Yamaoka N, Yamaguchi T, Otsuji E, Kato M, Kotani T, Kitamura K, Takahashi T
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Br J Cancer. 1994 Sep;70(3):405-8. doi: 10.1038/bjc.1994.318.
The monoclonal antibody (MAb) A7 has been used to treat patients with colorectal or pancreatic carcinoma with encouraging results. We therefore determined if MAb A7 would also react with gastric carcinoma cell lines. MAb A7 reacted with seven of eight gastric carcinoma cell lines tested. The intensity of the reaction, measured by flow cytometry, was equal to that of WiDr (colon) and HPC-YS (pancreas) cell lines. In nude mice bearing xenografts of the MAb A7-reactive gastric cancer line MKN45, the percentage injected dose of MAb A7 per g of tumour tissue on day 7 was 9.79; this value was 77% of that on day 1. The in vivo tumour-to-blood ratio of MAb A7 was 2.77 on day 7. Therefore, MAb A7 has long-term retention at binding sites as well as a high probability, high intensity and high specificity of reactivity against gastric cancer, which make it an ideal drug carrier for immunotargeted chemotherapy and immunodiagnosis.
单克隆抗体（MAb）A7已用于治疗结直肠癌或胰腺癌患者，效果令人鼓舞。因此，我们确定MAb A7是否也会与胃癌细胞系发生反应。MAb A7与所测试的8种胃癌细胞系中的7种发生反应。通过流式细胞术测量的反应强度与WiDr（结肠）和HPC-YS（胰腺）细胞系的反应强度相当。在携带MAb A7反应性胃癌细胞系MKN45异种移植物的裸鼠中，第7天每克肿瘤组织中MAb A7的注射剂量百分比为9.79；该值为第1天的77%。第7天MAb A7的体内肿瘤与血液比值为2.77。因此，MAb A7在结合位点具有长期滞留性，并且对胃癌具有高反应概率、高强度和高特异性，这使其成为免疫靶向化疗和免疫诊断的理想药物载体。
